

Veeda Oncology Management Team Experience

Matt Bowman - President & CEO

Mr. Bowman has over 25 years of experience within the pharmaceutical, and biotechnology and contract research organization (CRO) industry. Prior to Veeda, Matt was Senior Vice President, Chief Commercial Officer of Prologue Research International where he was responsible for all business and marketing/sales activities. Before joining Prologue Research, he served as Senior Vice President of Operations and Marketing for Neoprobe Corporation. While at Neoprobe, Mr. Bowman was involved with their oncology and immunological therapeutic portfolios, as well as the oncology instrumentation line for sentinel node biopsy. Prior to that, Mr. Bowman was with Pharmacia during which time he progressed through the organization as Product Manager, Marketing Manager, Director of Licensing and New Business Development, and Vice President of the Therapeutic Division. Mr. Bowman obtained his initial pharmaceutical experience in sales as well as marketing research. Matt brings to Veeda Oncology extensive strategic business experience from within the pharmaceutical, biotechnology and CRO industry as well as significant experience in successfully negotiating and completing a wide assortment of business agreements with his previous areas of responsibilities.

Kiran Marthak MD – Director

Dr. Marthak is a pioneer of clinical research activities in India with more than 25 years of clinical research experience. Dr. Marthak spent 13 years with Novartis where he was involved in Phase 1 studies as early as 1978-79 when phase I clinical research in India was virtually non-existent. He also initiated clinical trials for USFDA submission and data management while working with Pfizer as Vice President Clinical Research. Dr. Marthak also served as Vice President Clinical Research at Ranbaxy and with German Remedies as Medical Director.

During his career, Dr. Marthak has been invited to deliver lectures on the scope and conduction of clinical research in India by such noted institutions as Harvard Business School and Stanley Business School. He has served as the President for the Association of Medical Advisors of the Pharmaceutical Industry and was an Executive Committee Member for the International Federation of the Association of Pharmaceutical Physicians. Dr. Marthak has also served as one of the Board Members responsible for designing the modules for the Academy of Clinical Research. In addition, Dr. Marthak has been the Chief Organizer of the International Conference of Clinical Research held by CII-New Delhi, a faculty member for Pharmaceutical Medicine at the University of London, Fellow Member for the American College of Chest Physicians and the Royal Society of Medicine. He has also been actively involved with submissions to various regulatory authorities (e.g., US FDA, United Kingdom Medicines and Healthcare Regulatory Agency [MHRA], China State Food and Drug Administration [SFDA], South Africa Medicines Control Council [MCC], and Drugs Controller General of India [DCGI]).

Kathy Squillace - Vice President Clinical Operations

Ms. Squillace has over 30 years of research experience including 20 years in oncology. Initially, Ms. Squillace developed animal models at the National Institutes of Health (NIH) and later moved into the clinical arena. She worked in the oncology group at Adria (Pharmacia) and assisted in several New Drug Application (NDA) submissions. Ms. Squillace was the project planner for a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) which included approximately 35 Phase I and Phase II studies. For over 10 years, she worked as an independent consultant providing a wide range of oncology-focused services to such companies as Battelle Memorial Institute, Pharmacia and Upjohn, IDEC Pharmaceuticals, Neoprobe, and the Ohio State University.

Having worked as a Project Manager, Clinical Research Manager, Quality Assurance Auditor, Medical Writer and Senior Clinical Research Associate, Ms. Squillace has expertise in the planning and execution of clinical trials including protocol design, budget and timeline preparation, study initiation activities, Case Report Form (CRF) development, AE/SAE review and reporting, QA auditing, protocol and final study report writing and resource management. Ms. Squillace most recently was Senior Director of Clinical and Project Management at Prologue Research, an oncology CRO. In that role, she was responsible for Project Management, Clinical Projects, Medical Writing, Monitoring Services and Pharmacovigilance.

Dave Colborn - Vice President Data Management & IT

Dave Colborn has over 20 years of experience in oncology-related research. He graduated from The Ohio State University with a BS in Biochemistry. Mr. Colborn entered the pharmaceutical industry working at Pharmacia as an Assistant Pharmacologist and Associate Scientist where he was involved with in vitro and in vivo laboratory research and was responsible for providing software programming and computer support for bioanalytical, pharmacokinetic and safety analyses. Later, Mr. Colborn was a Research Associate at Ohio State University where he provided database development and support to the Comprehensive Cancer Center. Mr. Colborn has also been the manager of a clinical site network of 12 hospitals and 20 satellite offices that supported oncology trials. Over the last 5 years, he has been responsible for oversight of data management for clinical oncology trials in a Clinical Research Organization (CRO) setting. Mr. Colborn's experience spans both solid and liquid tumors as well as stem cell therapy and supportive care studies.

Sharon Jameson, BSN, MBA - Vice President Business and Network Development

Ms. Jameson earned her Bachelor's of Science in Nursing, and her Masters in Business Administration at Houston Baptist University, Houston, Texas. She has extensive experience in both the clinical and business aspects of clinical oncology, and has spent seven years in clinical practice in both the private practice and hospital settings, managing all aspects of cancer care delivery. Before joining Veeda Oncology, Sharon's professional appointments included Senior Director of ION Clinical Research, Vice President, Clinical Research Development at US Oncology, Director, Practice Outcomes Management at M.D. Anderson Cancer Center, and Business Manager for Mycobutin and Idarubicin at Adria Laboratories. In her role at both ION Clinical Research and US Oncology, she was responsible in the management of trial development, project and data management, analysis and reporting, and network development. During her time at Adria, Sharon played an instrumental role in the launch of these two products worldwide, by managing pre-launch activities, providing market-potential analysis, and directing all promotional initiatives, including educational and public relations efforts.

Trudie Seeger PhD - Global Head of QA/Regulatory

With more than 25 years of diversified drug development and management experience, Ms. Seeger has an expansive career portfolio focusing on all Regulatory and QA aspects of Phase I-IV investigational studies of both drug and devices, with a focus on oncology products. She managed the development of two ethical products from conception to market for a major pharmaceutical company as well as directed regulatory strategy of an innovative biotechnology product to marketing authorization in the US, Europe and Asia. She is intimately familiar with ICH, GCP, QSR and GMP regulations as they relate to manufacturing, design, execution, conduct, and reporting of studies in the US and internationally. She is able to develop all forms of clinical and regulatory documents related to product development and marketing approval including INDs, IDEs, and 510(k) s, PMAs, PDPs, NDAs and BLAs.

Ms. Seeger worked for 18 years in the pharmaceutical and biotech industry of which 14 years were in clinical research including positions as Clinical Research Associate, Project Manager, Director and Vice President. More recently, Ms. Seeger has utilized her QA and Regulatory experience and expertise in the field of Oncology to provide services to pharmaceutical, biologics, and the device industry.

Marie-Paule Derde PhD - Head of Biometrics

Dr. Derde is also a recognized Industrial Pharmacist who worked at the Université libre de Bruxelles (ULB) for 10 years in the Departments of Analytical Chemistry and Biostatistics.

In 1989, Dr. Derde founded DICE, a biometrics CRO. Upon its merger with Veeda Clinical Research in 2006, Dr. Derde continued in her role and has remained as General Manager in the Brussels office. Dr. Derde is also a visiting lecturer in the Master Program in Medical and Pharmaceutical Research (ULB), the Pharmed Program in Pharmacology and Pharmaceutical Medicine (ULB), and the Interuniversity Program in Industrial Pharmacy, as well as a statistical consultant at the Department of Reproductive Medicine of the VUB. She is the author of over 100 publications and two software packages in the fields of Chemometrics and Clinical Research.

Bruce Stouch, Ph.D. – Head of Biostatistics

Dr. Stouch has worked both domestically (FDA and CMS), and internationally (Canadian Ministry of Health, IQWiG, PMDA in Japan, and the EMEA) as an expert statistical resource for clients in preparing clinical trial designs and analyses in support of product labeling claims. Dr. Stouch has over 25 years of biostatistical analysis experience in pharmaceuticals, medical devices, and in vitro diagnostics. For twelve years, Dr. Stouch held the position of Director of Biostatistics and Scientific Data Management at Johnson & Johnson, where he was responsible for strategic development and implementation of pharmacoeconomic models for existing and emerging technologies in several therapeutic areas. Over the past decade, Dr. Stouch has served as a consultant to several leading pharmaceutical companies (Sanofi-Synthelabo, Abbott Laboratories, etc.) in designing adaptive clinical trials and prospective monitoring strategies based on conditional and predictive power. Dr. Stouch has been involved in over 50 publications and acknowledgements. Dr. Stouch received his Ph.D. in Biostatistics and Epidemiology through a cooperative program sponsored by Johnson & Johnson, with post-graduate studies at Temple University, Jefferson Medical College, and Harvard School of Public Health. Dr. Stouch also holds advanced degrees in mathematics and computer science.

Vivek Sood - Head Of Clinical Operations-India

Mr. Sood has over 10 years of experience in the pharmaceutical and clinical research industry. His vast experienced includes Phase I-IV clinical development across a variety of therapeutic areas but with a focus on oncology products. Prior to joining Veeda Oncology, Mr. Sood worked at a large international pharmaceutical company (Glaxo SmithKline Pharmaceuticals) as a sales executive and as a Senior Scientist at Dabur Research Foundation. Most recently, he worked at Reliance Clinical Research Services, an international CRO based in India. During his tenure at Reliance, Mr. Sood was the CRA for numerous oncology studies in both solid tumors and hematologic malignancies. He later moved into a Project Manager/Clinical Team leader role for large international Phase III oncology trials. He has expertise and experience in managing clinical operations for global oncology studies including ICH-GCP studies for submission to the FDA and EMEA.

Mr. Sood received both a Bachelor's and Master's degree in Pharmacy specializing in Pharmacology from Bangalore University and Punjabi University, respectively. He also received a post graduate diploma in computer applications from Punjabi University and a Master's certificate in Project Management from S P Jain Institute of Management & Research, Mumbai

Shamjith Das - Head of Data Management-India

Mr. Shamjith Das has over 10 years experience in clinical research, including more than 8 years experience in Clinical Data Management. Prior to joining Veeda Oncology, Mr. Shamjith Das worked for five years at Quintiles where he last served as the Group Head for Projects and Programming. He also worked at Tata Consultancy Service (TCS) as a Delivery Manager where he played a pivotal role in setting up the Clinical Data Management unit on a strategic and operational level, in order to facilitate growth of the CDM unit.

Mr. Das experience ranges from managing large off-shore projects across the continents to business development. His responsibilities have spanned the full duration of studies, from start-up to project close-out and review. Additionally, he has significant experience in implementing and executing various key Clinical Data Management Systems, Oracle databases and SAS®. He has worked across numerous therapeutic areas and has been instrumental in conducting various training programs within the CDM space.

Peter Michaelis MD - Head of German Unit

Peter Michaelis is a qualified Medical Doctor and a graduated Engineer. He worked in the pharmaceutical industry for a decade before working as a CEO in a full service Clinical Research Organization. Throughout his career, Dr Michaelis has gained extensive experience in clinical research in Western, Central and Eastern Europe.

Having a penchant for early drug development, he is now the Head of Veeda's unit in Görlitz, Germany, a recognized centre of excellence for Phase I clinical trials.

Tim Moore MD - Medical Director US/Medical Oncologist/Hematologist

Dr. Moore is board-certified in internal medicine, medical oncology and hematology. After completing a postdoctoral fellowship at the Ohio State University, Dr. Moore joined the National Cancer Institute as a senior investigator in the Clinical Investigations Branch and later at the Investigational Drug Branch of the Cancer Therapy Evaluation Program (CTEP). During his 5 years at NCI, he was responsible for drug development for a number of agents including Topoisomerase I inhibitors. He was also the project officer for the preclinical chemotherapy combination project while at CTEP. After his tenure at NCI, he returned to Ohio to join a hematology/oncology private practice, which is very active in investigational trials.

Dr. Moore is an active member of American Society of Clinical Oncology (ASCO) and American Society of Hematology (ASH) as well as the American College of Physicians and the American Medical Association. Dr. Moore has also been the Director of Palliative Care Service at Grant Medical Center in Columbus, Ohio since 1996. Dr. Moore has more than 20 publications, many of which focus on Phase I-II trials of new agents as well as quality of life issues in cancer patients.

Ralph V. Boccia, MD, FACP-Medical Director US/Medical Oncologist/Hematologist

Dr. Boccia is Clinical Associate Professor of Medicine at Georgetown University in Washington, DC, and Medical Director for the Center for Cancer and Blood Disorders in Bethesda, Maryland. He is also consulting Chief Medical Officer for the International Oncology Network (ION). Dr. Boccia completed training in internal medicine at the University of California, Los Angeles (UCLA) affiliated hospitals. His hematology, oncology, and bone marrow transplant fellowships were completed at the combined UCLA-VA Program and The National Cancer Institute at the National Institutes of Health in Bethesda, Maryland. He is a member of the Scientific Advisory Board of the Geriatric Oncology Consortium as well as many other professional societies including the American College of Physicians, American Society of Clinical Oncology, American Society of Hematology, and the American Society for Blood and Marrow Transplantation. With his vast experience and research, Dr. Boccia has published numerous articles in the Journal of Clinical Oncology, Cancer, Blood, Annals of Internal Medicine, Lancet, and Oncology among others. He is listed in Who's Who in America, and has been voted into America's Best Doctors, and Washingtonian's Best Physicians in Washington and Consumers' Checkbook's Guide to Top Doctors in Washington, DC every year since 1992.

Remy Brossel MD - Medical Oncologist Western Europe

Dr. Brossel is an oncologist by training and was a chief resident for four years in immuno-hemato-oncology in Paris followed by several years in private practice. He worked at Schering AG prior to founding the biotechnology company, Biologie et Industrie, along with his wife Dr. Sylvie Brossel. The initial focus of Biologie et Industrie was in developing monoclonal antibodies in cancer research in 1984. In 1991, the company changed its business focus and Dr. Brossel became a General CRO. In 1999, Biologie et Industrie migrated to specializing in providing clinical research services with the focus in the oncology biotechnology and orphan drugs arena.

Sylvie Brossel MD - Radiation Oncologist Western Europe

Prior to joining Veeda, Dr. Brossel along with her husband, Dr. Rémy Brossel, founded the biotechnology company, Biologie et Industrie, developing monoclonal antibodies in cancer research in 1984. In 1991, the company changed its business focus and became a General CRO. In 1999, Biologie et Industrie migrated to specializing in providing clinical research services with the focus in the oncology biotechnology and orphan drugs arena.

Leonard Kaufman, PhD – Consultant Biostatistician

Dr. Kauffman serves Veeda as a Consultant Biostatistician. In this capacity, he is responsible for providing statistical guidance in the design, analyses and reporting of oncology trials. Dr. Kaufman started his career in 1974 as a visiting professor at the Ecole des Hautes Etudes in Lille (France) and Univeriste du Zaire (Congo). In 1980, Dr. Kaufman spent six years as the Associate Professor at Vrize Universiteit Brussel (Free University of Brussels) followed by another six years as the full professor before becoming the head of the department of Biostatistics and Medical Informatics in 1991. With 34 years of experience in the field of Biostatistics and Medical Informatics, Dr. Kaufman brings expansive knowledge on best methods and practices for efficiently providing analytical results that summarize clinical trial protocol endpoints.